A Long-Term, Open-label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

Mary Hobart, Peter Zhang, Aleksandar Skuban, Claudette Brewer, Nanco Hefting, Raymond Sanchez, Robert D. McQuade
2019 Journal of Clinical Psychopharmacology  
Supplementary Table 1. Summary of safety outcomes over 52 weeks for patients with MDD receiving open-label adjunctive brexpiprazole 0.5-3 mg/day Safety population (n=2,938) Incidence of treatment-emergent suicidality,* % (n/N) C-SSRS Suicidal ideation 5.5 (161/2,938) C-SSRS Suicidal behavior 0.2 (7/2,938)
doi:10.1097/jcp.0000000000001034 fatcat:sv7zuyib75ghhfyb7gf7zu6iwe